Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.315
-0.005 (-0.38%)
Aug 15, 2025, 10:34 AM - Market open
Werewolf Therapeutics Revenue
In the year 2024, Werewolf Therapeutics had annual revenue of $1.89M, down -90.55%.
Revenue (ttm)
$1.89M
Revenue Growth
-90.55%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
46
Market Cap
59.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
Dec 31, 2022 | 16.40M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HOWL News
- 1 day ago - Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - GlobeNewsWire